FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

|--|

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  STAAB THOMAS R II							2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX								5. Relationship of Reporti (Check all applicable) Director X Officer (give title			son(s) to Iss 10% Ov Other (s	wner
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 03/01/2014								Λ	below) below) Senior Vice President and CFO				0
(Street) DURHAM NC 27703  (City) (State) (Zip)					- 4. If	Amer	ndmer	nt, Date	of Origin	al File	ed (Month/D	ay/Year)		. Indivine)	Form f	iled by One	e Rep	g (Check Aporting Person One Repo	on
		Tal	ole I - N	on-Deriv	ative	Sec	uriti	ies Ac	quirec	l, Di	sposed o	of, or Be	nefici	ally	Owned	t e			
Date				Date	. Transaction Date Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			Beneficially Owned Followir		es ally Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common	Stock			03/01/	2014	014			F		461(1)	D	\$11	69	126	5,616		D	
Common Stock 03/04/20					2014	014					3,000	A	\$4.	73	129	9,616		D	
Common Stock 03/04/20					2014	014			S		3,000	D	\$12.0	5 <b>9</b> <sup>(2)</sup>	126	5,616		D	
			Table II								oosed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		ar) if any	on Date,	4. Transa Code ( 8)		n of		6. Date E Expiration (Month/I	on Da		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amour or Number of Shares	r					
Emp. Stock Ontion	\$4 73	03/04/2014			М			3 000	03/01/2	)13	03/01/2022	Common	3 000		\$0	28 000	)	D	

## **Explanation of Responses:**

(Right to Buy)

- 1. Shares withheld by BioCryst Pharmaceuticals, Inc. upon the vesting of restricted stock to satisfy the reporting person's tax withholding obligations.
- 2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$12.69 to \$12.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

/s/ Alane P. Barnes, by power 03/07/2014 of attorney

\*\* Signature of Reporting Person

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.